Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916135 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL19719285 | 0.92 | HPGD (0.34) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL24658573 | 0.92 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL2606134 | 0.91 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL26012745 | 0.90 | POLB (0.32) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL18820989 | 0.90 | SMN1; SMN2 (0.35) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL18430819 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL12641902 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL24136297 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDHTTPOLBHSD17B10 | |
| SCHEMBL15627255 | 0.88 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDHTTPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | GENENTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11860156-B2 | Bioanalytical analysis of site-specific antibody drug conjugates | GENENTECH, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11753464-B2 | Methods and compositions for targeting polyubiquitin | GENENTECH, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753464-B2 | Methods and compositions for targeting polyubiquitin | GENENTECH, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230270875-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230265197-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265197-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080254024-A1 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME | GENENTECH, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080057066-A1 | METHODS AND COMPOSITIONS FOR TARGETING RELT | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070218069-A1 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | GENENTECH, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070081995-A1 | Methods and compositions for targeting IFNAR2 | GENENTECH, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | SMN1; SMN2 933/4885HPGD 4294/4885HTT 355/4885 |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | CD79B, CD99, BCL6 | SMN1; SMN2 4731/4885HPGD 4574/4885HTT 2710/4885 |
| US-20070081995-A1 | Methods and compositions for targeting IFNAR2 | IFNAR1, IFNG, EIF2AK2 | SMN1; SMN2 3208/4885HPGD 4534/4885HTT 1697/4885 |
| US-20070218069-A1 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | STUB1, UBQLN1, UBAP2 | SMN1; SMN2 4116/4885HPGD 4175/4885HTT 2737/4885 |
| US-11860156-B2 | Bioanalytical analysis of site-specific antibody drug conjugates | GUSB, DNPEP, FUCA2 | SMN1; SMN2 2894/4885HPGD 3199/4885HTT 2313/4885 |
| US-20080057066-A1 | METHODS AND COMPOSITIONS FOR TARGETING RELT | REL, FCGRT, IL6ST | SMN1; SMN2 3695/4885HPGD 4499/4885HTT 2004/4885 |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | SMN1; SMN2 3912/4885HPGD 3038/4885HTT 4322/4885 |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | PSMG3, STUB1, USP47 | SMN1; SMN2 2469/4885HPGD 4698/4885HTT 767/4885 |
| US-20230270875-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | CD79B, BCL6, BCL9 | SMN1; SMN2 4568/4885HPGD 4693/4885HTT 2855/4885 |
| US-11753464-B2 | Methods and compositions for targeting polyubiquitin | PSMG3, STUB1, USP47 | SMN1; SMN2 2469/4885HPGD 4698/4885HTT 767/4885 |
| US-20230265197-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | ERBB2, EGFR, ERBB3 | SMN1; SMN2 3595/4885HPGD 3269/4885HTT 677/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | SMN1; SMN2 2906/4885HPGD 679/4885HTT 2525/4885 |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | MUC1, PDIA6, LNPEP | SMN1; SMN2 4664/4885HPGD 2584/4885HTT 2840/4885 |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | IGSF11, MRPS18A, ANXA4 | SMN1; SMN2 3018/4885HPGD 4602/4885HTT 3371/4885 |
| US-20080254024-A1 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME | EPHB2, EPHB3, EPHB1 | SMN1; SMN2 2155/4885HPGD 3355/4885HTT 2456/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | SMN1; SMN2 4770/4885HPGD 3247/4885HTT 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.